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tmprovement in the invasive arm (mean difference +29.5, P=O.Ol, 18.5, P~0.04, respec- 
tively) and a trend in SAQ treatment satisfaction measure (mean difference +19.2, 
P=O.O7). All other measures were similar between the two arms. 
Conclusions: Patients undergoing invasive management after non-ST-segment eleva- 
tion AMI show improved functional status and quality of life. 
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administrated ix. 40 mg. before the first dose of 0.75 MU. of SK and 1 mg/kg every 12 
hours for 5-7 days. Heparin was infused 1000 i.u.ihour for 46-96 hoursThree noninva- 
sive reperfusion criteria were used: 1Rapid cessation of the chest pain. 2Rapid 
decreasing of the ST segment elevations by more than 50% from the initial value. 
3Rapid increasing of the CK and CK-MB with a peak within the first 12 hrs. 
Results. The chest pain-thrombolysis time was 143+/-71 min in the preASENOX sub- 
group, significantly shorter that the inASENOX subgroup (176+/-76 min., p=O.O16) and 
the StSK one (171+/-76 min., p=O.Oll). The ratios of the coronary repsrfusion were 
61.2%. 76.1% and 60.7%, respectively (preASENOX vs StSK p=O.O67; inASENOX vs 
StSK p=O.O44). The inhospital mortalities were: 3.12% (preASENOX); 5.9% (inASENOX) 
and 10.4% (StSK)(non-significant differences). Neither stroke nor other major haemorag- 
ical events were registered in the three subgroups. Simptomatic hypotansion was benign 
and appeared more frequent in the preASENOX (32%) and inASENOX (34%) subgroups 
as compared to the StSK one (20%). 
Conclusions: 1. The preASENOX and inASENOX regimens are safe and lead toward a 
significant higher ratios of coronary repetfusion as compared to the StSK one. 2. Our 
data sugest a very low mortality in patients treated with the preASENOX regimenfurther 
investigation are needed for certify this attractive regimen. 
1196-110 Left Ventricular Ejection Fraction, Enzyme Release, and 
Stent Implantation Are Independent Predictors of Late 
Clinical Outcome After Late Opening of Infarct-Related 
Occlusion 
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Seronde, Nicolas Meneveau, Jean-Pierre L. Bassand, University Hospital Jean-Mintoz, 
Besancon, France 
Background. The potential benefit of n-opening occluded infarct-related arteries (IRA) by 
percutaneous coronary intervention (PCI) is still debated. We assessed the immediate 
and long term clinical outcome of patients submitted to systematic attempt at IRA re- 
opening in a setting of a sub acute (a72 hours and cl0 days) myocardial infarction (Ml). 
Methods and Results. 199 consecutive patients matching these criteria were submitted 
to PCI and followed up for one year. Three endpoints were defined: (1) = composite of 
death, new Q wave MI, pert-procedural creatine kinase (CK) release >3 times the upper 
limit of normal, stroke, major bleeding or need for urgent revascularfsation at 30 days; (2) 
= one year survival without stroke, new MI or unstable angina; and (3) = endpoint #2 plus 
need for target lesion ravascularization. Reopening of the IRA was successful 159/199 
(60%) patients, with stem implantation in 99 (50%). Endpoint #f occurred in 16 (6%) 
patients; endpoint #2 in 30 (15%) and endpoint (3) in 44 (22%). Two year event free 
probability was 0.75*0.05 and 0.72a0.04 for endpoints #2 and #3 respectively. Left ven- 
tricular ejection fraction (LVEF) (odds ratio = 0.66 [0.79;0.94], p=O.OOl per additional per- 
cent of LVEF) and CK release (1.01 [l.OO;l.Ol], p=O.O4 per additional unit of CK 
released) were independent predictors for endpoint #2, with LVEF being the only inde- 
pendent predictor of endpoint #3. Lack of stem implantation (odds ratio = 0.26 [0.05:0.5]. 
p=O.O4) and CK release (1.01 [l.OO;l.Ol], p=O.O3) were independent predictors of death. 
Conclusion: Clinical outcome of patients submitted to systematic attempts to m-open 
occluded IRA in the setting defined in this study is mostly influenced by post Ml LV func- 
tion. Peri-procedural enzyme leakage and lack of stem implantation negatively influence 
late clinical outcome. 
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Background: Treatment with a macrolide antibiotic for patients (pts) with coronary artery 
disease may be only effective in pts with elevated antibody titers against Chlamydia 
pneumoniae(Cp). Methods: We therefore analyzed a pm-specified subgroup of the dou- 
ble-blind placebo controlled ANTIBIO study. Pts with an acute myocardial infarction were 
treated with either 300mgIod roxithromycin or pfacebolod for 6 weeks. A follow-up was 
performed at 12 months. In 160 out of 672 pts blood samples were analyzed for antibody 
titers (IgG, IgA and IgM by an enzyme linked immunoassay) against QI The combined 
endpoint (CE) was death, myocardial infarction, stroke, unstable angina, coronary bal- 
loon angioplasty or bypass surgery during 12 months follow up. Results: Positive anti- 
body titers against Cp were prevalent in 61.9% of pts for IgG, 55.6% for IgA and 1.9% for 
IgM. A CE occurred in 36% of pts being IgG seropositive compared to 32% in seronega- 
tive pts, and m 41% IgA seropositive versus 26% IgA seronegative pts (all p=ns). 61 pts 
received roxithromycin and 79 placebo. In the roxithromycin group a CE occurred in 42% 
of pts seropositive for IgG against Cpcompared to 26% in pts being seronegative (p=ns). 
In the placebo group CE occurred in 23% IgG seropositive pts versus 47% in seronega- 
tive pts (p=O.O25). No significant treatment effects were also seen according to preva- 
lence of IgA titers or in higher elevated titers. Conclusion: Neither seropositivity for C+I 
nor the amount of titer elevation was associated with a higher clinical event rate during 
12 month of follow up after an acute myocardial infarction. Treatment with roxithromycin 
did not influence the rate of clinical events, independently of presence or amount of anti- 
body titer elevation against Cp. 
1196-112 Safety and Efficacy of an Accelerated Streptokinase 
Regimen in Combination With Enoxaparin in the 
Prehospital Management of the ST Acute Myocardial 
Infarction (ASENOX-2) Study 
Gabriel Tatu-Chitoiu, Mircea Oprisan. Ovidiu Cismara, Rodica Marinescu, Ad& 
Marinescu, Radu Turcu, Maria Dorobantu, Spitalul Clinic de Urgenta. Bucuresti, 
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Background. Recent data suggest a similar efficacy of the standard Streptokinase (SK) 
regimen (1.5 M.U.160 min.) either in combination with Heparin or Enoxaparin in ST acute 
myocardial infarctton (STAMI). 
Objective Safety and efficacy of an accelerated SK regimen (0.75 M.U.00 min. 
repeated after 50 min. if no signs of coronary repertusion were detected) in combination 
with Enoxaparin was evaluated in the prehospital (preASENOX regimen) and the inhos- 
pital (inASENOX regimen) phase of STAMI and compared to the standard SK plus Hep- 
arin (StSK regimen). 
Methods. A group of 266 consecutive patients, thrombolised within the first 6 hours after 
the onset of STAMI was divided in three subgroups according to the mentioned regi- 
mens: preASENOX (64 pts.); inASENOX (67 pts) and StSK (135 pts.). Enoxaparin was 
1196-113 Erythropoietin Augments Cardiomyocyte Survival and 
Left Ventricular Function After Hypoxia 
Cvrus J. Parsa, Akio Matsumoto, G. Brant Walton, Jonathan S. Stamler, Walter J. Koch, 
Duke University, Durham, NC 
Background: Erythropoietin (EPO) may have effects beyond hematopoiesis such as 
prevention of neuronal apoptosis secondary to ischemia. We evaluated EPO protection 
in myocardial ischemia. Methods: H9c2 myoblasts were used to test EPCYs protection 
against hypoxia-induced apoptosis. Cells were pretreated with EPO (0.4 or lOU/ml) for 
24 hours (hrs) and exposed to hypoxia (95%b-5%CO,) for 12 hrs followed by 12 hrs of 
m-oxygenation, or H9c2 cells were treated with EPO after hypoxia and before re-oxygen- 
ation. Also, 250mM hjOs for 22 hrs was used as an apoptotic stimulus. Cells were 
stained and analyzed for % apoptotic nuclei. To apply our findings in viva. we used a 
model of myocardial infarction (Ml) in rabbits. Animals were randomized to receive a sin- 
gle dose of EPO (5000 units/kg) or saline or sham (no Ml). On post-operative day (POD) 
3, hemodynamic measurements were obtained. Hematocrits were drawn on POD 0, 1, 3, 
and 4. Hearts were harvested on POD 4 and infarct size quantified. Results: The graph 
shows that under all conditions tested, EPO prevented apoptosis in myoblasts.ln dvo, 3 
days after MI, EPO treated rabbits exhibited improved LV function, including contractility 
(~~0.05) and exhibited smaller infarct size. Protective effects were seen without 
increased hematocrit. Conclusions: EPO augmented myocyte survival after ischemia in 
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vitroand in viva, reduced infarct size and reversed ventricular dysfunction post-MI. Thus, 
EPO may offer novel protection for myocardial ischemia. 
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869-1 Influence of Smoking on Manifestation and Clinical 
Outcome of Acute ST Elevation Myocardial Infarction in 
Clinical Practice: Results of the ACOS Registry 
Christina Meisenzahl Anselm K. Gin, Rudolf Schiele. Harm Wienbergen. Tobias Heer. 
Martin G. Gottwik, Heruentrum Ludwigshafen, Ludwigshafen, Germany, Klinikum 
Niimberg Sod. Ntimberg, Germany 
Background: Subgroup-analysis of large randomised trials with selected patients have 
shown a lower mortalitv after ST Elevation Mvocardial Infarction (STEMI) in smokers 
I  
compared to nonsmokers. Little data exist on the differences in outcome of STEMI 
between smokers and nonsmokers in clinical practice. 
Methods: Since June 2000 consecutive patients (pts) with acute coronary syndrome 
(STEMI, Non-ST Elevation Myocardial Infarction and unstable angina) have been 
